Choi Jae Young, Jang Tae-Woo, Song Phil Hyun, Choi Seong Hoon, Ku Sae-Kwang, Song Chang-Hyun
Department of Urology, College of Medicine, Yeungnam University, Daegu 42415, Korea.
Department of Anatomy and Histology, College of Korean Medicine, Daegu Haany University, Gyeongsan 38610, Korea.
Antioxidants (Basel). 2022 Mar 18;11(3):580. doi: 10.3390/antiox11030580.
Metformin, the first-line drug for type 2 diabetes mellitus (T2DM), has additional effects on improvements of nonalcoholic fatty liver disease (NAFLD); however, there are no treatments for both T2DM and NAFLD. Previous studies have shown hepatoprotective effects of a mixture of lemon balm and dandelion (LD) through its antioxidant and anti-steatosis properties. Thus, combination effects of metformin and LD were examined in a high-fat diet (HFD)-induced metabolic disease mouse model. The model received an oral administration of distilled water, monotherapies of metformin and LD, or a metformin combination with LD for 12 weeks. The HFD-induced weight gain and body fat deposition were reduced more by the combination than either monotherapy. Blood parameters for NAFLD (i.e., alanine aminotransferase and triglyceride), T2DM (i.e., glucose and insulin), and renal functions (i.e., blood urea nitrogen and creatinine) were reduced in the combination. The combination further enhanced hepatic antioxidant activities, and improved insulin resistance via the AMP-activated protein kinase and lipid metabolism pathways. Histopathological analyses revealed that the metformin combination ameliorated the hepatic hypertrophy/steatosis, pancreatic endocrine/exocrine alteration, fat tissue hypertrophy, and renal steatosis, more than either monotherapy. These results suggest that metformin combined with LD can be promising for preventing and treating metabolic diseases involving insulin resistance.
二甲双胍是2型糖尿病(T2DM)的一线治疗药物,对改善非酒精性脂肪性肝病(NAFLD)也有额外作用;然而,目前尚无针对T2DM和NAFLD的联合治疗方法。先前的研究表明,柠檬香脂和蒲公英混合物(LD)通过其抗氧化和抗脂肪变性特性具有肝脏保护作用。因此,在高脂饮食(HFD)诱导的代谢性疾病小鼠模型中研究了二甲双胍与LD的联合作用。该模型口服蒸馏水、二甲双胍和LD单药治疗,或二甲双胍与LD联合治疗12周。与单一疗法相比,联合治疗对HFD诱导的体重增加和体脂沉积的减少作用更大。联合治疗降低了NAFLD的血液参数(即丙氨酸转氨酶和甘油三酯)、T2DM的血液参数(即血糖和胰岛素)以及肾功能参数(即血尿素氮和肌酐)。联合治疗进一步增强了肝脏抗氧化活性,并通过AMP激活的蛋白激酶和脂质代谢途径改善了胰岛素抵抗。组织病理学分析显示,与单一疗法相比,二甲双胍联合治疗对肝脏肥大/脂肪变性、胰腺内分泌/外分泌改变、脂肪组织肥大和肾脏脂肪变性的改善作用更大。这些结果表明,二甲双胍与LD联合使用有望预防和治疗涉及胰岛素抵抗的代谢性疾病。